MeSH term
Frequency | Condition_Probility | Female | 72 | 0.0 |
Humans | 213 | 0.0 |
Middle Aged | 69 | 0.0 |
Animals | 74 | 0.0 |
Brain/pathology | 21 | 6.0 |
Cattle | 16 | 0.0 |
English Abstract | 33 | 0.0 |
Risk Factors | 7 | 0.0 |
Sheep | 12 | 2.0 |
Adult | 60 | 0.0 |
Male | 88 | 0.0 |
Reference Values | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 107 | 0.0 |
Amyloid/analysis | 2 | 11.0 |
Brain/*pathology | 3 | 1.0 |
Creutzfeldt-Jakob Syndrome/pathology | 5 | 100.0 |
Gerstmann-Straussler-Scheinker Disease/pathology | 4 | 100.0 |
Hamsters | 10 | 0.0 |
Immunohistochemistry | 31 | 0.0 |
Kuru/pathology | 2 | 100.0 |
Microscopy, Electron | 14 | 0.0 |
Prion Diseases/*pathology | 3 | 75.0 |
Prions/*analysis | 4 | 80.0 |
Retrospective Studies | 6 | 0.0 |
Scrapie/pathology | 2 | 100.0 |
Amyloid/genetics | 3 | 23.0 |
Codon | 15 | 3.0 |
DNA Mutational Analysis | 7 | 0.0 |
Incidence | 3 | 0.0 |
Molecular Biology/methods | 2 | 7.0 |
Point Mutation/genetics | 2 | 0.0 |
Protein Precursors/genetics | 4 | 4.0 |
Aged | 33 | 0.0 |
Brain Chemistry | 6 | 2.0 |
Creutzfeldt-Jakob Syndrome/metabolism/pathology | 5 | 62.0 |
Gerstmann-Straussler-Scheinker Disease/metabolism/pathology | 4 | 100.0 |
Immunoenzyme Techniques | 4 | 0.0 |
Sensitivity and Specificity | 2 | 0.0 |
Staining and Labeling | 4 | 0.0 |
Polymorphism, Genetic | 9 | 0.0 |
Prions/*genetics | 22 | 40.0 |
Amino Acid Substitution | 5 | 0.0 |
Computer Simulation | 2 | 0.0 |
Mutation | 25 | 0.0 |
Peptide Fragments/*chemistry | 2 | 6.0 |
Prions/*chemistry | 3 | 50.0 |
Protein Folding | 3 | 0.0 |
Protein Structure, Secondary | 6 | 0.0 |
Brain/metabolism | 7 | 1.0 |
Gene Expression | 4 | 0.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Mice | 35 | 0.0 |
Mice, Knockout | 3 | 0.0 |
Mice, Transgenic | 11 | 0.0 |
Models, Molecular | 3 | 0.0 |
PrPC Proteins/genetics | 2 | 50.0 |
Prion Diseases/*genetics | 3 | 60.0 |
Follow-Up Studies | 4 | 0.0 |
Skin/pathology | 4 | 1.0 |
Time Factors | 10 | 0.0 |
*Amino Acid Substitution | 2 | 2.0 |
Amyloid/*genetics | 6 | 16.0 |
Codon/genetics | 6 | 1.0 |
Gerstmann-Straussler-Scheinker Disease/*genetics | 9 | 90.0 |
*Point Mutation | 7 | 0.0 |
Protein Precursors/*genetics | 8 | 6.0 |
Autophagocytosis/*physiology | 2 | 33.0 |
Biopsy | 3 | 0.0 |
Brain/*ultrastructure | 2 | 66.0 |
Creutzfeldt-Jakob Syndrome/*pathology | 4 | 57.0 |
Insomnia, Fatal Familial/pathology | 2 | 100.0 |
Vacuoles/physiology | 2 | 66.0 |
Carpal Tunnel Syndrome/*drug therapy | 2 | 100.0 |
Double-Blind Method | 4 | 0.0 |
Prospective Studies | 4 | 0.0 |
Treatment Outcome | 2 | 0.0 |
Binding Sites | 2 | 0.0 |
Gerstmann-Straussler-Scheinker Disease/*genetics/metabolism | 4 | 100.0 |
Glycosylation | 2 | 0.0 |
Peptide Fragments/chemistry | 2 | 1.0 |
Protein Conformation | 5 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 51 | 0.0 |
Subcellular Fractions/metabolism | 2 | 0.0 |
Diagnosis, Differential | 6 | 0.0 |
Age Factors | 3 | 0.0 |
Aged, 80 and over | 5 | 0.0 |
Comparative Study | 23 | 0.0 |
Cross-Sectional Studies | 3 | 0.0 |
Educational Status | 3 | 4.0 |
Health Surveys | 2 | 2.0 |
Regression Analysis | 4 | 0.0 |
Prions/genetics | 7 | 70.0 |
Amyloid beta-Protein/*analysis | 2 | 18.0 |
Brain/metabolism/pathology | 3 | 2.0 |
Disease Models, Animal | 4 | 0.0 |
Predictive Value of Tests | 4 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
Alleles | 4 | 0.0 |
Cerebral Cortex/pathology | 4 | 8.0 |
Heterozygote | 4 | 0.0 |
Syndrome | 5 | 0.0 |
Brain/metabolism/*pathology | 2 | 6.0 |
Cerebellum/pathology | 2 | 6.0 |
Pedigree | 17 | 0.0 |
Tomography, Emission-Computed, Single-Photon | 3 | 5.0 |
Amino Acid Sequence | 18 | 0.0 |
Mesocricetus | 4 | 2.0 |
Molecular Sequence Data | 32 | 0.0 |
Mutation/genetics | 3 | 0.0 |
Prions/*chemistry/genetics/*metabolism | 2 | 100.0 |
X-Ray Diffraction | 2 | 2.0 |
Antibodies, Monoclonal/*diagnostic use | 2 | 0.0 |
Creutzfeldt-Jakob Syndrome/*genetics | 7 | 36.0 |
Phenotype | 14 | 0.0 |
*Antiretroviral Therapy, Highly Active | 3 | 0.0 |
Drug Resistance, Viral/*genetics | 3 | 16.0 |
HIV Infections/*drug therapy/genetics | 2 | 28.0 |
*HIV-1 | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 2 | 0.0 |
Treatment Failure | 2 | 0.0 |
Viral Load | 2 | 0.0 |
Cells, Cultured | 3 | 0.0 |
Prions/chemistry/*genetics | 2 | 50.0 |
Spectroscopy, Fourier Transform Infrared | 2 | 4.0 |
Gerstmann-Straussler-Scheinker Disease/*genetics/*pathology | 2 | 100.0 |
Japan | 3 | 0.0 |
Neurofibrillary Tangles/*pathology | 3 | 13.0 |
Age of Onset | 3 | 0.0 |
Family Health | 2 | 0.0 |
Fatal Outcome | 2 | 0.0 |
Point Mutation | 13 | 0.0 |
Prion Diseases/*genetics/pathology | 2 | 66.0 |
Blotting, Western | 6 | 0.0 |
Disease Transmission | 2 | 15.0 |
Homozygote | 2 | 0.0 |
Brain/*metabolism/pathology | 2 | 2.0 |
Iatrogenic Disease | 2 | 25.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
Creutzfeldt-Jakob Syndrome/etiology | 5 | 100.0 |
Kuru/etiology | 3 | 100.0 |
Adolescent | 13 | 0.0 |
Body Height | 2 | 1.0 |
Child | 7 | 0.0 |
Magnetic Resonance Imaging | 4 | 0.0 |
*Mutation | 11 | 0.0 |
Gerstmann-Straussler-Scheinker Disease/*physiopathology | 2 | 100.0 |
Callithrix | 2 | 2.0 |
Vacuoles/pathology | 2 | 16.0 |
Neoplasm Staging | 2 | 0.0 |
Prognosis | 3 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
*Prions | 2 | 66.0 |
Zoonoses | 2 | 50.0 |
Creutzfeldt-Jakob Syndrome/*genetics/pathology | 2 | 40.0 |
Cats | 2 | 0.0 |
Goats | 4 | 4.0 |
Encephalopathy, Bovine Spongiform/epidemiology | 2 | 100.0 |
Administration, Oral | 2 | 0.0 |
Questionnaires | 2 | 0.0 |
*Severity of Illness Index | 2 | 3.0 |
Evaluation Studies | 2 | 0.0 |
Glaucoma, Open-Angle/*classification/physiopathology | 2 | 100.0 |
Image Processing, Computer-Assisted | 2 | 0.0 |
Perimetry/*methods/statistics & numerical data | 2 | 100.0 |
Creutzfeldt-Jakob Syndrome/*metabolism/pathology | 2 | 66.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Gerstmann-Straussler-Scheinker Disease/*metabolism/pathology | 2 | 100.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Prions/*genetics/metabolism | 4 | 57.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Rats | 6 | 0.0 |
Polymerase Chain Reaction | 10 | 0.0 |
Models, Genetic | 2 | 0.0 |
Personality Inventory | 2 | 5.0 |
Risk | 2 | 0.0 |
Sex Factors | 3 | 0.0 |
Chromosomes, Human, Pair 20 | 3 | 6.0 |
Mutation/*genetics | 2 | 0.0 |
Genes, Structural | 2 | 0.0 |
Gerstmann-Straussler-Scheinker Disease/genetics/pathology | 2 | 66.0 |
Isomerism | 2 | 0.0 |
Species Specificity | 2 | 0.0 |
Amyloid/metabolism | 2 | 4.0 |
Immunoblotting | 4 | 0.0 |
Sequence Analysis, DNA | 3 | 0.0 |
*Polymorphism, Genetic | 3 | 0.0 |
Gerstmann-Straussler-Scheinker Disease/genetics | 5 | 83.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Chromosomes, Human, Pair 8 | 2 | 1.0 |
Elastic Tissue/pathology | 2 | 50.0 |
Molecular Biology | 3 | 1.0 |
Base Sequence | 17 | 0.0 |
Genotype | 5 | 0.0 |
Gerstmann-Straussler-Scheinker Disease/*genetics/pathology | 5 | 100.0 |
Chromosome Mapping | 2 | 0.0 |
Amyloid/*metabolism | 5 | 9.0 |
DNA/analysis | 2 | 0.0 |
Staining and Labeling/methods | 2 | 1.0 |
Chromosome Mapping/*methods | 2 | 1.0 |
Cosmids | 2 | 0.0 |
*Models, Genetic | 2 | 1.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Creutzfeldt-Jakob Syndrome/genetics | 4 | 40.0 |
Gerstmann-Straussler-Scheinker Disease/*pathology | 3 | 100.0 |
PrPC Proteins/*genetics | 2 | 40.0 |
Atrophy | 3 | 2.0 |
Neurologic Examination | 2 | 1.0 |
Neuropsychological Tests | 2 | 0.0 |
Combined Modality Therapy | 2 | 0.0 |
Codon/*genetics | 4 | 6.0 |
Chromatography, Gel | 2 | 0.0 |
DNA Primers | 2 | 0.0 |
Indiana | 2 | 33.0 |
Gerstmann-Straussler-Scheinker Disease/etiology | 2 | 100.0 |
DNA/genetics | 3 | 0.0 |
Prion Diseases/genetics | 2 | 66.0 |
Models, Biological | 2 | 0.0 |
PrPSc Proteins | 24 | 85.0 |
Kuru/*metabolism/pathology | 2 | 100.0 |
Prions/*metabolism | 2 | 22.0 |
Amyloid beta-Protein/*metabolism | 2 | 2.0 |
Prions/metabolism | 2 | 66.0 |
Encephalopathy, Bovine Spongiform/transmission | 2 | 100.0 |
Scrapie/genetics | 5 | 71.0 |
Peptides/chemistry | 2 | 0.0 |
Amyloid beta-Protein Precursor/*genetics | 3 | 4.0 |
Sampling Studies | 2 | 1.0 |
Gerstmann-Straussler-Scheinker Disease/metabolism/*pathology | 2 | 100.0 |
Brain/*pathology/ultrastructure | 3 | 30.0 |
Prions/genetics/isolation & purification | 2 | 100.0 |
Cell-Free System | 2 | 0.0 |
*Genome, Protozoan | 2 | 66.0 |
*Codon | 2 | 4.0 |
Alzheimer Disease/*pathology | 2 | 3.0 |
Fluorescent Antibody Technique | 3 | 0.0 |
Microscopy, Immunoelectron | 2 | 0.0 |
Prions/genetics/metabolism | 2 | 50.0 |
Alzheimer Disease/*metabolism/pathology | 2 | 2.0 |
Creutzfeldt-Jakob Syndrome/microbiology | 2 | 100.0 |
PrPC Proteins | 2 | 50.0 |
Prions/*genetics/pathogenicity | 2 | 66.0 |
Open Reading Frames | 2 | 0.0 |
Viral Proteins/*genetics | 5 | 6.0 |
Oligonucleotide Probes | 2 | 0.0 |
United States | 2 | 0.0 |
PrP 27-30 Protein | 2 | 100.0 |
Immunohistochemistry/*methods | 2 | 2.0 |
Cloning, Molecular | 2 | 0.0 |
Slow Virus Diseases/*genetics | 2 | 100.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
Amyloid/*immunology | 2 | 50.0 |
Immune Sera/immunology | 2 | 1.0 |
Immunochemistry | 4 | 1.0 |
France | 2 | 0.0 |
Gerstmann-Straussler-Scheinker Disease/*metabolism | 2 | 100.0 |
Protein Isoforms | 3 | 0.0 |
Amyloidosis/pathology | 2 | 50.0 |
Alzheimer Disease/metabolism/*pathology | 2 | 6.0 |
Histocytochemistry | 3 | 0.0 |
Immunoglobulins/analysis | 2 | 0.0 |
Brain/*metabolism | 2 | 0.0 |
Drug Synergism | 2 | 0.0 |
Phylogeny | 2 | 0.0 |
Amyloidosis/complications/*immunology/metabolism | 2 | 100.0 |
Complement/*metabolism | 2 | 1.0 |
Creutzfeldt-Jakob Syndrome/complications/*immunology/metabolism | 2 | 100.0 |
Kuru/immunology/metabolism | 2 | 100.0 |
Serum Amyloid P-Component/metabolism | 2 | 33.0 |
Slow Virus Diseases/complications/*immunology/metabolism | 2 | 100.0 |
Cerebellar Ataxia/genetics/pathology/*transmission | 2 | 100.0 |
Dementia/*genetics/pathology | 2 | 33.0 |
Nerve Degeneration | 2 | 3.0 |
Aging | 2 | 0.0 |
Blood-Brain Barrier | 2 | 3.0 |
Dementia/*etiology/genetics/pathology | 2 | 100.0 |
Disease Susceptibility | 2 | 0.0 |
Gerstmann Syndrome/genetics | 2 | 100.0 |
Slow Virus Diseases/*complications | 2 | 100.0 |
